The Ranitidine in Sodium Chloride in, cataloged under National Stock Number 6505-01-371-7070, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Glaxo Wellcome Inc. Government technical data includes 8 specifications, cited from the U.S. Government catalog. The record lists 1 manufacturer part number for this item, enabling identification through both NSN and commercial part number lookups. 4 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: PG.
| Parameter | Value |
|---|---|
| NSN | 6505-01-371-7070 |
| Primary Part Number | NDC00173-0441-00 |
| Item Name | Ranitidine in Sodium Chloride in |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Glaxo Wellcome Inc |
| Status | ACTIVE |
| Therapeutic Equivalent | ZANTAC BY GLAXO |
| Administration | INTRAVENOUS |
| Primary Container Content Quantity | 50.000 MILLILITERS |
| Supplementary Features | FOR USE W/INTRAVENOUS ADMINISTRATION SETS |
| Medical Designation and Grade | UNITED STATES PHARMACOPEIA |
| Primary Container Type | BAG WITH HANGING DEVICE, PLASTIC |
| Active Medicament Medicinal Strength | 50.000 MILLIGRAMS RANITIDINE EQUIVALENT |
| Total Primary Container Quantity | 24 |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | PG |
| Part Number | Manufacturer |
|---|---|
| NDC00173-0441-00 PRIMARY | Glaxo Wellcome Inc (USA) |
| Reference | Meaning |
|---|---|
| ZANTAC INJECTION PREMIXED | 5/1 Secondary reference Glaxo Wellcome Inc |
| ZANTAC | 5/1 Secondary reference Glaxo Wellcome Inc |
| 6505NCM116383 | 5/1 Secondary reference Defense Medical Standardization Board |
| 23781 | 5/1 Secondary reference U.S. Government activity |
NSN 6505-01-371-7070 is a Ranitidine in Sodium Chloride in, manufactured by Glaxo Wellcome Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-371-7070 has 1 manufacturer part number on file: NDC00173-0441-00 (Glaxo Wellcome Inc).
Key specifications for NDC00173-0441-00: Therapeutic Equivalent: ZANTAC BY GLAXO; Administration: INTRAVENOUS; Primary Container Content Quantity: 50.000 MILLILITERS; Supplementary Features: FOR USE W/INTRAVENOUS ADMINISTRATION SETS. 8 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.